Clinical Trials Logo

Lupus Erythematosus, Systemic clinical trials

View clinical trials related to Lupus Erythematosus, Systemic.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05430854 Terminated - Clinical trials for Systemic Lupus Erythematosus

Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study

RECAST SLE OLE
Start date: June 1, 2022
Phase: Phase 2
Study type: Interventional

A Phase 2, Open-Label Extension study to evaluate the long-term safety and tolerability of daxdilimab in participants with Systemic Lupus Erythematosus completing the treatment period of the RECAST SLE clinical study.

NCT ID: NCT05203419 Terminated - Clinical trials for Lupus Erythematosus, Systemic

Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)

Start date: March 15, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this two-part multiple ascending dose study is to evaluate the safety and tolerability of multiple doses of MHS552 in adults with mild to moderately active Systemic Lupus Erythematosus (SLE). Participants will be treated for 4 or 12 weeks followed by an 8-week follow-up period.

NCT ID: NCT05140824 Terminated - Clinical trials for Systemic Lupus Erythematosus (SLE)

A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus

Start date: December 30, 2021
Phase: Phase 1
Study type: Interventional

A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Doses of TJ202 in Patients with Systemic Lupus Erythematosus

NCT ID: NCT04839315 Terminated - Osteoarthritis Clinical Trials

COVID-19 Vaccination in Rheumatic Disease Patients

Start date: February 15, 2021
Phase: Early Phase 1
Study type: Interventional

The research is being done to study the immune responses to COVID-19 vaccination in patients with rheumatic diseases.

NCT ID: NCT04809623 Terminated - Clinical trials for Cutaneous Lupus Erythematosus

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

LYNX
Start date: September 1, 2021
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the safety and tolerability of edecesertib (formerly GS-5718) in participants with cutaneous lupus erythematosus (CLE) with or without systemic lupus erythematosus (SLE).

NCT ID: NCT04700267 Terminated - Clinical trials for Systemic Lupus Erythematosus

A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Systemic Lupus Erythematosus

TAPINOMA
Start date: December 28, 2020
Phase: Phase 1
Study type: Interventional

This is a first exploration of GLPG3970 in subjects with active systemic lupus erythematosus (SLE) to evaluate the effect on disease biomarkers and to determine its pharmacokinetics (PK) profile, safety and tolerability, and pharmacodynamics (PD) biomarkers related to the investigational product (IP) mechanism of action and the pathophysiology of SLE.

NCT ID: NCT04680637 Terminated - Clinical trials for Active Systemic Lupus Erythematosus

Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus

Start date: May 6, 2021
Phase: Phase 2
Study type: Interventional

The primary objective is to evaluate the efficacy and safety of efavaleukin alfa in subjects with active systemic lupus erythematosus.

NCT ID: NCT04335747 Terminated - Clinical trials for Rheumatoid Arthritis

COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases

Start date: April 23, 2020
Phase:
Study type: Observational

The trial is a prospective, observational study aiming to identify risk factors for serious COVID-19 infection by evaluating clinical measures and biomarkers of inflammation in patients with inflammatory rheumatic disease hospitalized with COVID-19 compared with control groups.

NCT ID: NCT03958955 Terminated - Clinical trials for Discoid Lupus Erythematosus

Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.

Start date: July 9, 2019
Phase: Phase 2
Study type: Interventional

This was a double-blind, multi-centre, randomised, vehicle-controlled, within-subject phase 2a trial. The trial was designed to establish the efficacy and safety of delgocitinib cream in the treatment of adult subjects with discoid lupus erythematosus (DLE).

NCT ID: NCT03953261 Terminated - Clinical trials for Systemic Lupus Erythematosus

Effect of Curcumin on Systemic Lupus Erythematosus

Start date: September 1, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this investigator initiated study is to determine the efficacy of curcumin on disease activity of subjects with systemic lupus erythematous. Curcumin has been found to have anti-inflammatory effects and has been found to improve disease activity in lupus patients. In addition, subjects with rheumatoid arthritis as well as osteoarthritis have also found benefit for their disease activity.